Exelixis, Inc. financial data

Symbol
EXEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1851 Harbor Bay Parkway, Alameda, California
State of incorporation
Delaware
Fiscal year end
January 3
Latest financial report
Q1 2024 - Apr 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 380 % -31.1%
Quick Ratio 6.2 % -36.5%
Debt-to-equity 28 % +30.6%
Return On Assets 6.91 % +35.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 291 M shares -10.5%
Common Stock, Shares, Outstanding 295 M shares -9.22%
Entity Public Float 4.7 B USD -31.2%
Common Stock, Value, Issued 295 K USD -9.23%
Weighted Average Number of Shares Outstanding, Basic 301 M shares -7.29%
Weighted Average Number of Shares Outstanding, Diluted 306 M shares -6.36%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.85 B USD +11%
Research and Development Expense 1.04 B USD +7.03%
Costs and Expenses 1.68 B USD +10.4%
Operating Income (Loss) 172 M USD +16.6%
Income Tax Expense (Benefit) 53.5 M USD +22.4%
Net Income (Loss) Attributable to Parent 205 M USD +33.4%
Earnings Per Share, Basic 0.65 USD/shares +35.4%
Earnings Per Share, Diluted 0.65 USD/shares +38.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 260 M USD -52%
Inventory, Net 21.1 M USD -29.4%
Assets, Current 1.29 B USD -21.1%
Deferred Income Tax Assets, Net 362 M USD +57.5%
Property, Plant and Equipment, Net 127 M USD +9.47%
Operating Lease, Right-of-Use Asset 233 M USD -0.67%
Goodwill 63.7 M USD 0%
Other Assets, Noncurrent 280 M USD +108%
Assets 2.8 B USD -10.8%
Accounts Payable, Current 26.1 M USD -20.1%
Contract with Customer, Liability, Current 4.05 M USD -42.6%
Liabilities, Current 373 M USD +13.9%
Contract with Customer, Liability, Noncurrent 4.92 M USD -21.9%
Operating Lease, Liability, Noncurrent 201 M USD +7.77%
Other Liabilities, Noncurrent 101 M USD +50.3%
Liabilities 676 M USD +14.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5.2 M USD +44%
Retained Earnings (Accumulated Deficit) -259 M USD -4562%
Stockholders' Equity Attributable to Parent 2.13 B USD -16.7%
Liabilities and Equity 2.8 B USD -10.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 68.8 M USD -18.5%
Net Cash Provided by (Used in) Financing Activities -184 M USD -4113%
Net Cash Provided by (Used in) Investing Activities 112 M USD
Common Stock, Shares Authorized 400 M shares 0%
Common Stock, Shares, Issued 295 M shares -9.22%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3.43 M USD -109%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 260 M USD -52.1%
Deferred Tax Assets, Valuation Allowance 83 M USD +7.47%
Deferred Tax Assets, Gross 498 M USD +37.9%
Operating Lease, Liability 216 M USD +3.77%
Payments to Acquire Property, Plant, and Equipment 9.69 M USD -19.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 209 M USD +38.4%
Lessee, Operating Lease, Liability, to be Paid 316 M USD -1.18%
Property, Plant and Equipment, Gross 209 M USD +21.9%
Operating Lease, Liability, Current 25.7 M USD +45.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.6 M USD +8.16%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.3 M USD +45.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 79.3 M USD -10.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 26.2 M USD +13.3%
Deferred Tax Assets, Operating Loss Carryforwards 29.5 M USD -12.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 116 M USD +32%
Lessee, Operating Lease, Liability, to be Paid, Year Four 27 M USD +14.2%
Additional Paid in Capital 2.39 B USD -6.51%
Depreciation, Depletion and Amortization 6.38 M USD -6.96%
Deferred Tax Assets, Net of Valuation Allowance 415 M USD +46.2%
Share-based Payment Arrangement, Expense 109 M USD +4.14%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%